-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60

Benzinga·08/25/2026 09:40:44
Listen to the news
Piper Sandler analyst Yasmeen Rahimi initiates coverage on AgomAb Therapeutics (NASDAQ:AGMB) with a Overweight rating and announces Price Target of $60.